This Metric Says You Are Smart to Buy ISIS Pharmaceuticals, Inc. (ISIS)

Page 1 of 2

Is ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) worth your attention right now? Investors who are in the know are taking an optimistic view. The number of bullish hedge fund bets advanced by 9 in recent months.

In the financial world, there are dozens of indicators investors can use to watch Mr. Market. A couple of the most underrated are hedge fund and insider trading activity. At Insider Monkey, our studies have shown that, historically, those who follow the best picks of the best money managers can outperform the S&P 500 by a solid amount (see just how much).

Equally as integral, optimistic insider trading activity is another way to parse down the stock market universe. Just as you’d expect, there are many incentives for a corporate insider to downsize shares of his or her company, but only one, very simple reason why they would initiate a purchase. Many academic studies have demonstrated the impressive potential of this strategy if piggybackers understand what to do (learn more here).

Consequently, let’s take a gander at the key action regarding ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS).

What have hedge funds been doing with ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS)?

In preparation for this quarter, a total of 14 of the hedge funds we track were long in this stock, a change of 180% from one quarter earlier. With the smart money’s capital changing hands, there exists a few noteworthy hedge fund managers who were boosting their stakes substantially.

Of the funds we track, Visium Asset Management, managed by Jacob Gottlieb, holds the largest position in ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS). Visium Asset Management has a $17.6 million position in the stock, comprising 0.5% of its 13F portfolio. Sitting at the No. 2 spot is Millennium Management, managed by Israel Englander, which held a $11.9 million position; the fund has 0.1% of its 13F portfolio invested in the stock. Some other hedge funds that are bullish include Joseph Edelman’s Perceptive Advisors, SAC Subsidiary’s Sigma Capital Management and Louis Bacon’s Moore Global Investments.

As aggregate interest increased, key hedge funds were breaking ground themselves. Visium Asset Management, managed by Jacob Gottlieb, assembled the biggest position in ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS). Visium Asset Management had 17.6 million invested in the company at the end of the quarter. Israel Englander’s Millennium Management also made a $11.9 million investment in the stock during the quarter. The other funds with new positions in the stock are Joseph Edelman’s Perceptive Advisors, SAC Subsidiary’s Sigma Capital Management, and Louis Bacon’s Moore Global Investments.

What do corporate executives and insiders think about ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS)?

Insider buying is most useful when the company in question has seen transactions within the past six months. Over the last six-month time period, ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) has experienced zero unique insiders buying, and 8 insider sales (see the details of insider trades here).

Let’s check out hedge fund and insider activity in other stocks similar to ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS). These stocks are United Therapeutics Corporation (NASDAQ:UTHR), Cubist Pharmaceuticals Inc (NASDAQ:CBST), Amarin Corporation plc (ADR) (NASDAQ:AMRN), Taro Pharmaceutical Industries Ltd. (NYSE:TARO), and The Medicines Company (NASDAQ:MDCO). This group of stocks are the members of the drug manufacturers – other industry and their market caps resemble ISIS’s market cap.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 Top Reasons For Getting Fired

The 3 Best States to Start an LLC

10 Jobs That Allow You to Travel

7 High-Paying Jobs You Can Do From Home

12 Best Cities to Shop in USA

10 Best States To Practice Medicine

The 10 Best States to Have a Business

The 12 Most Expensive Apple (AAPL) Apps in the Market

The 10 Richest Billionaires in the World

10 Biggest Kickstarter Failures

The 10 Best Places to Work At

The Top 10 of Google Inc (GOOGL)’s Most Expensive Acquisitions

13 Best Cities to Visit in South America

10 Most Expensive Works of Art of All Time

The 10 Richest Banks in the World

The 10 Best-Paying Jobs in America (2014)

7 Most Expensive Foods in the World

The World’s Top 10 Earning Authors

Five Wicked and Very Expensive Items (and Other “Stuff”) Sold on eBay

10 Biggest Celebrity Bankruptcies

The Top 10 Highest Paid CEOs in 2014

The 10 Most Expensive Real Estate Cities in America

10 Most Expensive States To Live In America

The 10 Best Airlines in the World

The 10 Best-Selling Cars in 2014

The 10 Best Industries to Invest In

The 10 Most Expensive States to Own a Car In

Top 10 Business Schools in US: 2014 Rankings

Top 20 Female Billionaires in 2014

6 Movies That You Should Watch to Better Understand The Cold War

Top 15 Best Paying Jobs for Women in 2014

Top 6 Things Rich People Do Differently Every Day

5 Retirement Mistakes To Avoid (and Einstein’s Famous Quote)

11 Smartest People in the World

6 Films About the Financial World You Need To Watch (While “The Wolf” is Not Around)

Warren Buffett and Billionaires Are Crazy About These 7 Stocks

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!